- Home
- NODK vs AKBA Comparison
NODK vs AKBA Comparison
Compare NODK & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- AKBA
- Stock Information
- Founded
- NODK 1946
- AKBA 2007
- Country
- NODK United States
- AKBA United States
- Employees
- NODK N/A
- AKBA N/A
- Industry
- NODK Property-Casualty Insurers
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- AKBA Health Care
- Exchange
- NODK Nasdaq
- AKBA Nasdaq
- Market Cap
- NODK 322.1M
- AKBA 336.2M
- IPO Year
- NODK 2017
- AKBA 2014
- Fundamental
- Price
- NODK $15.27
- AKBA $1.82
- Analyst Decision
- NODK
- AKBA Strong Buy
- Analyst Count
- NODK 0
- AKBA 2
- Target Price
- NODK N/A
- AKBA $5.75
- AVG Volume (30 Days)
- NODK 31.2K
- AKBA 2.3M
- Earning Date
- NODK 11-15-2024
- AKBA 11-07-2024
- Dividend Yield
- NODK N/A
- AKBA N/A
- EPS Growth
- NODK N/A
- AKBA N/A
- EPS
- NODK N/A
- AKBA N/A
- Revenue
- NODK $380,700,000.00
- AKBA $169,879,000.00
- Revenue This Year
- NODK N/A
- AKBA N/A
- Revenue Next Year
- NODK N/A
- AKBA $3.23
- P/E Ratio
- NODK N/A
- AKBA N/A
- Revenue Growth
- NODK 15.43
- AKBA N/A
- 52 Week Low
- NODK $12.02
- AKBA $0.80
- 52 Week High
- NODK $16.55
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- NODK 56.81
- AKBA 68.47
- Support Level
- NODK $15.37
- AKBA $1.30
- Resistance Level
- NODK $16.09
- AKBA $2.01
- Average True Range (ATR)
- NODK 0.22
- AKBA 0.12
- MACD
- NODK 0.01
- AKBA 0.04
- Stochastic Oscillator
- NODK 70.93
- AKBA 78.52
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.